2018
DOI: 10.1089/trgh.2017.0026
|View full text |Cite
|
Sign up to set email alerts
|

Mammary Myofibroblastoma in a Transgender Patient on Feminizing Hormones: Literature Review and Case Report

Abstract: Purpose: Defining the risk of neoplasia associated with gender-affirming hormone therapy (GAHT) is a priority for transgender medical research. The purposes of this article are to present a unique case of breast neoplasia in a transgender individual and to review the existing evidence base on GAHT as a potential risk for breast pathology.Methods: We present the case of a 76-year-old transgender patient who developed an estrogen receptor-positive mammary myofibroblastoma (MFB) after 13 months of treatment on fe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
7
0
1

Year Published

2018
2018
2022
2022

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 15 publications
(8 citation statements)
references
References 43 publications
0
7
0
1
Order By: Relevance
“…Some patients were documented with gynecomastia (8) and that evidence suggests a role of the estrogen pathway. Interestingly, O'Bryan et al recently published the first case of MFB occurring in a transgender individual after 13 months of treatment with hormone replacement therapy (9). In 1998, Morgan and Pitha postulated that androgen receptor or its ligands could be pathologically related to the development of MFB, but the results did not resolutely prove a causal mechanism of hormonal tumorigenesis (10).…”
Section: Discussionmentioning
confidence: 99%
“…Some patients were documented with gynecomastia (8) and that evidence suggests a role of the estrogen pathway. Interestingly, O'Bryan et al recently published the first case of MFB occurring in a transgender individual after 13 months of treatment with hormone replacement therapy (9). In 1998, Morgan and Pitha postulated that androgen receptor or its ligands could be pathologically related to the development of MFB, but the results did not resolutely prove a causal mechanism of hormonal tumorigenesis (10).…”
Section: Discussionmentioning
confidence: 99%
“…Mujer transgénero de 76 años que desarrolló un miofibroblastoma mamario (MFB) con receptores de estrógenos positivos después de 13 meses de tratamiento con hormonas feminizantes. La lesión no palpable fue encontrada en mamografía (14).…”
Section: En Otras Publicaciones Se Recopilaron Los Siguientes Casos C...unclassified
“…This larger team created the first rural-based patient registry for gender-expansive pediatric patients in the country and we have begun publishing our data. Team members also contribute to the field with abstracts, case reports and book chapters [48,[52][53][54][55][56][57][58][59][60].…”
Section: Advancing Evidence-based Carementioning
confidence: 99%